ACoP13

InSysBio to take part in ACoP13

events

Conference

October 12, 2022

InSysBio announces its participation in the Thirteenth American Conference on Pharmacometrics (ACoP13) which is to be held in person from October 30th to November 2nd, 2022, at the Gaylord Rockies Resort & Convention Center in Aurora, Colorado. The theme of ACoP13 is “Together Moving Mountains”. InSysBio team is going to present 7 posters in frames of the Conference, namely:

Monday, October 31

M-006: "Virtual Patients Parallel Simulations in a Hybrid Cloud Environment" by Ivan Borisov, Evgeny Metelkin, Tatiana Karelina, Oleg Demin
M-057: "Quantitative systems pharmacology model for neurofilament L dynamics in multiple sclerosis and under immunomodulatory therapies" by Polina Pchelintseva

Tuesday, November 1

T-040: "Quantitative systems pharmacology modeling of immune response role in Parkinson’s disease" by Tatiana Karelina
T-051: "Methodological aspects of rate law derivation of cell dynamics processes: focus on QSP model development" by Oleg Demin, Maria Mironovich, Julia Sergienko
T-054: "Estimation of Imax and IC50 for PD1-PDL1 inhibition of T cell proliferation" by Oleg Demin
T-061: "The QSP model of microglia role in tau pathology and neurodegeneration" by Stepan Lerner
T-065: "Pharmacokinetics modeling and optimal dose prediction for a bispecific antibody against CD40 and PD1" by Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Edinburgh, UK (INSYSBIO UK LIMITED), Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

←	December 2019	→
Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Upcoming Events

Mo	Tu	We	Th	Fr	Sa	Su
←	December 2019					→
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31